References
- 42 C.F.R. 493.17 – Test categorization. ( 1993). In Legal Information Institute. Retrieved from http://www.law.cornell.edu/cfr/text/42/493.17#a
- 42 C.F.R. 493.5 – Categories of tests by complexity. ( 1995). In Legal Information Institute. Retrieved from https://www.law.cornell.edu/cfr/text/42/493.5
- American Psychiatric Association. ( 2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: American Psychiatric Publishing.
- American Society of Addiction Medicine. ( 2011). Definition of addiction. Retrieved from http://www.asam.org/for-the-public/definition-of-addiction
- American Society of Addiction Medicine. ( 2013). Drug testing: A white paper of the American Society of Addiction Medicine (ASAM). Retrieved from http://www.asam.org/docs/default-source/publicy-policy-statements/drug-testing-a-white-paper-by-asam.pdf?sfvrsn=2
- American Society of Addiction Medicine. ( n.d.). Treatment. Retrieved from http://www.asam.org/research-treatment/treatment
- Bertholf, R. L., & Reisfield G. ( 2014). The case for point-of-care drug testing. Retrieved from http://www.medlabmag.com/article/1141/MarchApril_2014/The_Case_for_PointofCare_Drug_Testing/
- Boschloo, L., Vogelzangs, N., Smit, J. H., Van Den Brink, W., Veltman, D. J., Beekman, A. T. F., & Penninx, B. W. J. H. ( 2011). Comorbidity and risk indicators for alcohol use disorders among persons with anxiety and/or depressive disorders. Journal of Affective Disorders. 131(1–3); 233–242.
- Brandhorst, G., Oellerich, M., Maine, G., Taylor, P., Veen, G., & Wallemacq, P. ( 2012). Liquid chromatography–tandem mass spectrometry or automated immunoassays: what are the future trends in therapeutic drug monitoring? Clinical Chemistry, 58(5), 821–825.
- Center for Substance Abuse Treatment. ( 2005a). Medication-assisted treatment for opioid addiction in opioid treatment programs. A Treatment Improvement Protocol (TIP) 43. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK64164/pdf/TOC.pdf
- Center for Substance Abuse Treatment. ( 2005b). Substance abuse treatment: Group therapy. Treatment Improvement Protocol (TIP) Series 41. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK64220/pdf/TOC.pdf
- Center for Substance Abuse Treatment. ( 2006). Substance abuse: Clinical issues in intensive outpatient treatment. A Treatment Improvement Protocol (TIP) 47. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK64093/pdf/TOC.pdf
- Centers for Disease Control and Prevention. ( n.d.). Deaths from prescription opioid overdose. Retrieved from http://www.cdc.gov/drugoverdose/data/overdose.html
- Centers for Medicare and Medicaid Services. ( 2015). Local coverage determination (LCD): Controlled substance monitoring and drugs of abuse. Retrieved from https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35724&ContrId=380&ver=21&ContrVer=1&CntrctrSelected=380*1&Cntrctr=380&DocType=Active&s=All&bc=AggAAAIAAAAAAA%3d%3d&
- Cerda, M., Wall, M., Keyes, K. M., Galea, S., & Hasin, D. ( 2012). Medical marijuana laws in 50 states: Investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug and Alcohol Dependence. 120(1–3), 22–27.
- Chang, Y. P., & Compton, P. ( 2013). Management of chronic pain with chronic opioid therapy in patients with substance use disorders. Addiction Science & Clinical Practice. 8(1), 21.
- Collen, M. ( 2012). Profit-driven drug testing. Journal of Pain & Palliative Care Pharmacotherapy. 26(1), 13–17.
- De Hoffman, E., & Stroobant, V. ( 2007). Mass spectrometry: Principles and applications. West Sussex, UK: Wiley. Retrieved from http://www.usp.br/massa/2014/qfl2144/pdf/MassSpectrometry.pdf
- Evans, D. G. ( 2013). The economic impacts of marijuana legalization. Journal of Global Drug Policy and Practice. Retrieved from http://jpo.wrlc.org/bitstream/handle/11204/3240/The%20Economic%20Impacts%20of%20Marijuana%20Legalization.pdf?sequence=3
- Fareed, A., Stout, S., Casarella, J., Vayalapalli, S., Cox, J., & Drexler, K. ( 2011). Illicit opioid intoxication: diagnosis and treatment. Substance Abuse, 5, 17–25.
- Frezza, C. ( 2013). Medical marijuana: a drug without a medical model. Georgetown Law Journal. 101: 1117–1145.
- Gourlay, D. L., Caplan, Y. H., & Heit, H. A. ( 2006). Urine drug testing in clinical practice: Dispelling the myths & designing strategies. Retrieved from http://www.mc.uky.edu/equip-4-pcps/documents/section8/urine%20drug%20testing%20in%20clinical%20practice.pdf.
- Gourlay, D. L., Heit, H. A., & Caplan, Y. H. ( 2012). Urine drug testing in clinical practice: The art and science of patient care. Retrieved from http://eo2.commpartners.com/users/ama/downloads/udt5_Copy.pdf
- Gudin, J. A., Mogali, S., Jones, J. D., & Comer, S. D. ( 2013). Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgraduate Medical Journal. 125(4), 115–130.
- Hammett-Stabler, C. A., & Webster, L. R. ( 2008). A clinical guide to urine drug testing: Augmenting pain management & enhancing patient care. Retrieved from http://paindr.com/wp-content/uploads/2012/06/A-Clinical-Guide-to-URINE-DRUG-TESTING.pdf
- Katz, N. P., Adams, E. H., Chilcoat, H., Colucci, R. D., Comer, S. D., Goliber, P., … Weiss, R. ( 2007). Challenges in the development of prescription opioid abuse-deterrent formulations. The Clinical Journal of Pain, 23(8), 648–660.
- Leavitt, S. B., & Reisfield, G. M. ( 2012). Introducing “understanding urine drug testing in pain care.” Retrieved from http://updates.pain-topics.org/2012/08/introducing-understanding-udt-in-pain.html
- Mayer, S. ( 2015). Proving personal use: the admissibility of evidence negating intent to distribute marijuana. Michigan Law Review, 113, 1255–1270.
- Mayo Clinic. ( 2014). Symptoms. Retrieved from http://www.mayoclinic.org/diseases-conditions/drug-addiction/basics/symptoms/con-20020970
- Melanson, S. E. ( 2012). The utility of immunoassays for urine drug testing. Clinics in Laboratory Medicine, 32, 429–447.
- Montgomery, E. ( 2011). Trends in immunoassays for drugs-of-abuse testing. Medical Laboratory Observer, 43(8), 17.
- Nichols, J. H., Christenson, R. H., Clarke, W., Gronowski A., Hammett-Stabler, C..A., Jacobs, E., … Zucker, M..L. ( 2007). Executive summary. The national academy of clinical biochemistry laboratory medicine practice guideline: evidence-based practice for point-of-care testing. Clinica Chimica Acta, 379(1–2), 14–28.
- Owen, G. T., Burton, A. W., Schade, C..M., & Passik, S. ( 2012). Urine drug testing: current recommendations and best practices. Pain Physician, 15, ES119–ES133.
- Palmetto GBA. ( 2015). Controlled substance monitoring and drugs of abuse coding and billing guidelines. Retrieved from http://www.palmettogba.com/palmetto/providers.nsf/DocsCat/Providers∼JM%20Part%20B∼Browse%20by%20Topic∼Lab∼9SDPFR2173?open&navmenu=Browse%5Eby%5ETopic%7C%7C%7C%7C
- Powers, E. J., Nishimi, R. Y., & Kizer, K. W. ( 2005). Evidence-based treatment practices for substance use disorders. Retrieved from http://www.apa.org/divisions/div50/doc/Evidence_-_Based_Treatment_Practices_for_Substance_Use_Disorders.pdf/
- Premera Blue Cross. ( 2014). Medical policy updates. Retrieved from https://www.premera.com/documents/026567_09-13-2014.pdf
- Reisfield, G. M., Webb, F. J., Bertholf, R. L., Sloan, P. A., & Wilson, G. R. ( 2007). Family physicians' proficiency in urine drug test interpretation. Journal of Opioid Management. 3(6), 33–37.
- Starrels, J. L., Fox, A. D., Kunins, H. V., & Cunningham, C. O. ( 2012). They don't know what they don't know: Internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain. Journal of General Internal Medicine. 27(11), 1521–1527.
- Substance Abuse and Mental Health Services Administration. ( 2012). Clinical drug testing in primary care. Technical Assistance Publication Series (TAP) 32. Retrieved from http://store.samhsa.gov/shin/content/SMA12-4668/SMA12-4668.pdf
- Substance Abuse and Mental Health Services Administration. ( 2013). Systems-level implementation of screening, brief intervention, and referral to treatment. Technical Assistance Publication (TAP) 33. Retrieved from http://www.integration.samhsa.gov/sbirt/tap33.pdf
- Substance Abuse and Mental Health Services Administration. ( 2015). Medication and counseling treatment. Retrieved from http://www.samhsa.gov/medication-assisted-treatment/treatment
- Substance Abuse and Mental Health Services Administration. ( n.d.). Briefing on substance use treatment and recovery in the United States. Retrieved from http://www.samhsa.gov/sites/default/files/partnersforrecovery/docs/Briefing_Substance_Use_Treatment.pdf
- Tate, J., & Ward, G. ( 2004). Inferences in immunoassay. The Clinical Biochemist Reviews. 25(2), 105–120.
- Weimer, B. J., Kennedy, E. K., & Graham, P. W. ( 2007). Social indicator study to assess substance use prevention needs in metropolitan statistical areas in Georgia. Retrieved from http://dmh.mo.gov/docs/ada/rpts/Reports%20Archive/MissouriSocialIndicatorsfinalreport_Nov2002.pdf
- Young, N. K., Nakashian, M., Yeh, S., & Amatetti, S. ( 2006). Screening and assessment for family engagement, retention, and recovery (SAFER). Retrieved from https://www.ncsacw.samhsa.gov/files/SAFERR.pdf